(Q35082170)

6 August 2017

1 reference

title

Cell-cycle dysregulation and anticancer therapy (English)

1 reference

6 August 2017

Jennifer A. Pietenpol

series ordinal

3

object named as

Jennifer A Pietenpol

1 reference

6 August 2017

Zoe A Stewart

1

1 reference

PubMed ID

12628359

6 August 2017

Matthew D Westfall

series ordinal

2

1 reference

6 August 2017

1 March 2003

1 reference

Trends in Pharmacological Sciences

6 August 2017

1 reference

6 August 2017

24

1 reference

6 August 2017

3

1 reference

6 August 2017

139-145

1 reference

CDK inhibitors: positive and negative regulators of G1-phase progression

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

How the cyclin became a cyclin: regulated proteolysis in the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The retinoblastoma gene: a prototypic and multifunctional tumor suppressor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Checking out the G(2)/M transition.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

When checkpoints fail

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

p53 Signaling and cell cycle checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The physiology of p16(INK4A)-mediated G1 proliferative arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Cell cycle checkpoint signaling through the ATM and ATR kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

p53 regulation of G(2) checkpoint is retinoblastoma protein dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

14-3-3sigma is a p53-regulated inhibitor of G2/M progression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

p53 regulates a G2 checkpoint through cyclin B1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Cdc25C interacts with PCNA at G2/M transition

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The spindle checkpoint: structural insights into dynamic signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Selected novel anticancer treatments targeting cell signaling proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Tumor suppressor p53 mutations and breast cancer: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Functions of the MDM2 oncoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The MDM2 gene amplification database

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Decreased expression of p57(KIP2)mRNA in human bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Cancer risk and the ATM gene: a continuing debate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Mutations of mitotic checkpoint genes in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Cell cycle molecular targets in novel anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Pharmacological inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The role of G2-block abrogation, DNA double-strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Histone deacetylase inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

A gene expression database for the molecular pharmacology of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Use of isogenic human cancer cells for high-throughput screening and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Genetic selection of peptide inhibitors of biological pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

Functional discovery via a compendium of expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900026-9

7 January 2021

10.1016/S0165-6147(03)00026-9

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12628359